12 results about "Mtt method" patented technology

The invention provides a dual-targeting carrier material, a preparation method thereof and a preparation method of oleanolic acid nanoparticles wrapped by the dual-targeting carrier material, and belongs to the technical field of medicines. The oleanolic acid targeting nanoparticles are prepared by taking a dual-targeting high-molecular copolymer as a carrier material and adopting an emulsification-solvent evaporation method, so that the oleanolic acid can be protected from being quickly degraded, and the in-vivo circulation time of the oleanolic acid can be prolonged. Meanwhile, targeted delivery of oleanolic acid is realized through a targeted group, the concentration of the drug in tumor tissues is improved, and toxic and side effects on normal tissues are reduced. An MTT method is adopted, the inhibition effect of the oleanolic acid nanoparticles on cell growth is researched, and the result shows that the oleanolic acid targeting nanoparticles have a stronger effect of inhibiting tumor cell proliferation compared with an oleanolic acid raw material medicine.

The invention provides a medical instrument skin stimulation test data processing method based on an artificial skin model, and relates to the technical field of skin stimulation tests. Collecting the original OD value of each pore in the 96-pore plate under the wavelength of 570nm; calculating the survival rate and the standard deviation of the positive control group and the test sample group; verifying the data validity of the negative control group and the positive control group; and performing skin irritation judgment according to the average survival rate of the test sample group to obtain a skin irritation type. According to the method, the in-vitro skin model based on HTWSkinRHE is established, strict standardized culture conditions and grouping design are adopted, the batch-to-batch consistency and data comparability of the experimental model are remarkably improved, and the model can better meet more medical instrument requirements; the cell activity is detected by simulating a complete skin layered structure and combining an MTT method, and the judgment threshold value is highly matched with the in-vivo stimulation response.

The present invention discloses a novel ether derivative of epilichexol and its synthesis method and application. The new synthesis method uses oak moss (methyl 2,4-dihydroxybenzoate) as the starting material for compound synthesis to synthesize epilichexol and its derivatives. In this method, the corresponding intermediate phenol or acid is first synthesized, and finally the phenolic acid compounds are synthesized by esterification condensation, and finally the ether compounds are synthesized, effectively avoiding the unstable factors directly derived on the basis of esters, which is efficient and convenient and is an effective way suitable for the synthesis of phenolic acid compounds. Through the MTT method for detecting cytotoxicity experiments, these ether compounds are all toxic to MDCK cells and have cytotoxicity to cancer cells A549, HePG2 and 22RV1, indicating potential anti-tumor activity, which is of great significance for the treatment of anti-tumor diseases.

The application discloses the application of Huaxingdan in the preparation of a glioma drug in the technical field of biology and medicine, detects the influence of Huaxingdan on the proliferation activity of glioma cells U251, U87 and A172 by using an MTT method in vitro, finds that Huaxingdan has a significant inhibitory effect on the proliferation of glioma cells, and is time and concentration dependent. The influence of Huaxingdan on the apoptosis of glioma cells U87 is detected by using a flow cytometry, and it is found that Huaxingdan can induce the apoptosis of U87 cells, and is concentration dependent. The animal experiment shows that Huaxingdan can effectively inhibit the growth of glioma cells in vivo, and the HE staining shows that Huaxingdan has no toxicity in vivo, and can be used as a drug for preventing and treating glioma.

The present application belongs to the technical field of medicine, and particularly relates to a NAMPT inhibitor, a composition, a preparation method and use, a structural formula of which is: or R 1 H or Br; M is C or N, Y is C or N, Z is C or N; n=0, 1 or 2, or L is an amino group, a thiourea group, a urea group, R 2 H, CH3, CF3, OCH3, F or Cl; R is H, a methyl group, an ethyl group, an isopropyl group or a cyclopropyl group; X is F, Cl or Br; the compound of the present application is determined by an MTT method to have an effect of inhibiting proliferation of gastric cancer cells, has significant anti-gastric cancer activity, and has higher activity than that of apatinib at a cell level, and can be used for preparing an anti-gastric cancer drug.

The application discloses an immune regulation pharmaceutical effect analysis method based on a concentrated pill of psammochloa and astragalus, which comprises the following steps: raw material extraction, animal model construction, multi-dimensional detection and data statistics. The raw materials of psammochloa and astragalus are weighed according to a specific ratio, and then are prepared into extract by ethanol decoction and concentration. After the experimental animals are grouped and administered intragastrically, the individuals are screened by the four oxygen pyrimidine modeling. The immune organs are separated, weighed, and the index is calculated. The contents of various cytokines in serum and liver tissue are detected by the ELISA method. The tissue morphology, lymphocyte proliferation and protein expression are observed by HE staining, MTT method and immunofluorescence method. The expression of key signal pathway proteins is detected by electrophoresis and other steps after the total protein is extracted, and statistical analysis is carried out. The method is systematic and comprehensive, the result is accurate and reliable, and a scientific basis is provided for the immune regulation pharmaceutical effect evaluation of the concentrated pill.

The invention discloses application of an AKT inhibitor or an STAT3 inhibitor in preparation of a medicine for overcoming drug resistance of bladder cancer to an MEK inhibitor, and belongs to the field of biological medicine. Detecting the cell activity through an MTT method; a Western blot experiment is adopted to detect a key target protein or gene expression level, a bladder cancer drug-resistant cell ERK abnormal activation + STAT3 / Akt compensation activation mechanism is defined, p-ERK, p-STAT3 and p-Akt are locked as targets, the drug resistance of bladder cancer to an MEK inhibitor is overcome through an AKT inhibitor or an STAT3 inhibitor, the scheme can accurately inhibit abnormal pathways, reverse drug resistance and improve treatment sensitivity, and the method is safe and suitable for clinical application. A new direction is provided for patients with drug-resistant bladder cancer, and the clinical bottleneck of the MEK inhibitor is helped to be broken through.

The invention discloses a 17-hydroxy-jolkinolide B (HJB) coupled triphenylphosphine derivative as well as a preparation method and application thereof, and belongs to the technical field of antitumor drugs, the 17-hydroxy-jolkinolide B coupled triphenylphosphine derivative has the following structural formula: # imgabs0 #, and n is equal to 1-3. According to the invention, an effective component HJB extracted from euphorbia fischeriana is taken as a raw material, triphenylphosphine cations are introduced to C-17 site of HJB through esterification reaction and substitution reaction, and in-vivo and in-vitro antitumor activity evaluation of a novel derivative is carried out through an MTT method, laser confocal microscopy observation, flow cytometry and an animal transplantation tumor method. It is found that the novel derivative has relatively low toxicity to human normal mammary epithelial cells MCF-10A while retaining relatively good anti-tumor activity to human liver cancer HepG-2, human breast cancer MDA-MB-231, human lung cancer H1975 and human gastric cancer MNK45 cells, and can obviously inhibit growth of transplanted tumors in Balb / c mice. The 17-hydroxy-jolkinolide B coupled triphenylphosphine derivative disclosed by the invention has the potential of being developed into a new anti-tumor drug.

The invention belongs to the technical field of biological medicines, and particularly relates to a 2-(substituted) phenyl-2H-indazole7-carboxamide compound as well as a preparation method and application thereof. The antitumor cell proliferation activity of the compound is evaluated by adopting an MTT method cancer cell proliferation inhibition experiment, and experimental data shows that the compounds with the structures as shown in the formula I and the formula II provided by the invention show clear and relatively strong antitumor cell proliferation activity; the conclusion proves that the 2-(substituted) phenyl-2H-indazole7-carboxamide compounds with the structures as shown in the formula I and the formula II have the possibility of being developed into novel anti-tumor therapeutic drugs.

The invention discloses an enantiomer-kaurane diterpene compound derivative and application thereof in preparation of anti-tumor metastasis drugs or inhibitors. According to the invention, it is determined that the DKA derivative has no obvious cytotoxic activity through an MTT method; tannwell cell experiments and scratch experiments prove that compared with DKA, the activity of the designed and synthesized DKA derivative for inhibiting cell migration is remarkably enhanced.

The present invention relates to the technical field of pharmaceutical chemistry, and specifically discloses a cytochalasin compound with a novel skeleton type of 5 / 5 / 13 tricyclic system isolated from endophytic fungi of Fritillaria hupehensis Boeremia exigua . The cell viability was detected by the MTT method. The experimental results showed that the compound had obvious inhibitory activity against MCF-7 (human breast cancer cells), and the IC 50 value was 11.81 mM.

The invention discloses a method for separating compounds from persistent calyx of physalis alkekengi. Belongs to the field of physalis alkekengi persistent According to the invention, physalin compounds 1, 2 and 3 separated from petroleum ether and ethyl acetate parts of persistent calyx of physalis alkekengi are screened by adopting an MTT (Methyl Thiazolyl Tetrazolium) method. The physalin compound 1 and the physalin compound 2 provided by the invention have the growth inhibition rates of 19.61% and 15.20% on tumor cells MDA-MB-231 respectively, and have a relatively weak growth inhibition rate on the tumor cells; the growth inhibition rate of the compound 3 on tumor cells SW480 is 13.18%, and the compound 3 has weak growth inhibition on the cells.